CADENCE PHARMACEUTICALS INC Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2013 12 months to Dec 31, 2013	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011
Revenues:
Product revenue, net
License revenue
Total net revenues
Costs and expenses:
Cost of product sales
Amortization of patent license
Research and development
Selling, general and administrative
Impairment of long-lived assets
Other
Total costs and expenses
Loss from operations
Other (expense) income:
Interest income
Interest expense
Other income
Total other income (expense), net
Loss before income tax
Net loss
Basic and diluted net loss per share
Shares used to compute basic and diluted net loss per share

Comments